Update on the treatment of Behçet’s syndrome
- 25 January 2019
- journal article
- review article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 14 (5) , 661-675
Abstract
Behçet’s syndrome (BS) is a complex disease that shows important heterogeneity in clinical findings and physiopathology. Its treatment can be problematic as BS manifestations in different organs may respond differently to the same drug. The cornerstone of therapy for inducing remission is corticosteroids whereas immunomodulatory and immunosuppressive agents such as colchicine, azathioprine, cyclosporine-A, interferon-alpha, and cyclophosphamide are used as steroid-sparing agents and to prevent further relapses. However, a considerable number of patients continue to have mucocutaneous lesions despite therapy, and some patients require more aggressive treatment for refractory major organ involvement. Tumor necrosis factor alpha inhibitors, especially infliximab and adalimumab, are increasingly used for various refractory BS manifestations despite the lack of controlled studies. In this review, we aim to focus on both the traditional and new treatment modalities for BS, with more emphasis on recent data on newer agents.Keywords
This publication has 110 references indexed in Scilit:
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Pulmonary Artery Involvement and Associated Lung Disease in Behçet DiseaseMedicine, 2012
- Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 PatientsSeminars in Arthritis and Rheumatism, 2011
- A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week studyRheumatology, 2010
- Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study)International Journal of Rheumatic Diseases, 2010
- Effects of interferon α treatment on the clinical course of refractory Behçet's disease: an open studyAnnals of the Rheumatic Diseases, 2003
- Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's diseaseJournal of Internal Medicine, 1998
- Interteron alfa-2a in the Treatment of Behçet’s DiseaseDermatology, 1996
- Interferon therapy for Behçet's diseaseJournal of the American Academy of Dermatology, 1994
- A Controlled Trial of Azathioprine in Behçet's SyndromeNew England Journal of Medicine, 1990